Lewy Body Dementia: An Overview of Promising Therapeutics.

IF 4.8 2区医学 Q1 CLINICAL NEUROLOGY

Current Neurology and Neuroscience Reports Pub Date : 2023-10-01 Epub Date: 2023-08-12 DOI:10.1007/s11910-023-01292-0

Irina A Skylar-Scott, Sharon J Sha

{"title":"Lewy Body Dementia: An Overview of Promising Therapeutics.","authors":"Irina A Skylar-Scott, Sharon J Sha","doi":"10.1007/s11910-023-01292-0","DOIUrl":null,"url":null,"abstract":"Purpose of review: Lewy body dementia (LBD) encompasses dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). This article will emphasize potential disease-modifying therapies as well as investigative symptomatic treatments for non-motor symptoms including cognitive impairment and psychosis that can present a tremendous burden to patients with LBD and their caregivers.Recent findings: We review 11 prospective disease-modifying therapies (DMT) including four with phase 2 data (neflamapimod, nilotinib, bosutinib, and E2027); four with some limited data in symptomatic populations including phase 1, open-label, registry, or cohort data (vodabatinib, ambroxol, clenbuterol, and terazosin); and three with phase 1 data in healthy populations (Anle138b, fosgonimeton, and CT1812). We also appraise four symptomatic therapies for cognitive impairment, but due to safety and efficacy concerns, only NYX-458 remains under active investigation. Of symptomatic therapies for psychosis recently investigated, pimavanserin shows promise in LBD, but studies of nelotanserin have been suspended. Although the discovery of novel symptomatic and disease-modifying therapeutics remains a significant challenge, recently published and upcoming trials signify promising strides toward that aim.","PeriodicalId":10831,"journal":{"name":"Current Neurology and Neuroscience Reports","volume":" ","pages":"581-592"},"PeriodicalIF":4.8000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Neurology and Neuroscience Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11910-023-01292-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Lewy body dementia (LBD) encompasses dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). This article will emphasize potential disease-modifying therapies as well as investigative symptomatic treatments for non-motor symptoms including cognitive impairment and psychosis that can present a tremendous burden to patients with LBD and their caregivers.

Recent findings: We review 11 prospective disease-modifying therapies (DMT) including four with phase 2 data (neflamapimod, nilotinib, bosutinib, and E2027); four with some limited data in symptomatic populations including phase 1, open-label, registry, or cohort data (vodabatinib, ambroxol, clenbuterol, and terazosin); and three with phase 1 data in healthy populations (Anle138b, fosgonimeton, and CT1812). We also appraise four symptomatic therapies for cognitive impairment, but due to safety and efficacy concerns, only NYX-458 remains under active investigation. Of symptomatic therapies for psychosis recently investigated, pimavanserin shows promise in LBD, but studies of nelotanserin have been suspended. Although the discovery of novel symptomatic and disease-modifying therapeutics remains a significant challenge, recently published and upcoming trials signify promising strides toward that aim.

查看原文本刊更多论文

路易体痴呆症：前景广阔的治疗学综述。

综述目的：路易体痴呆症（LBD）包括路易体痴呆（DLB）和帕金森病痴呆（PDD）。这篇文章将强调潜在的疾病改良疗法，以及针对非运动症状的研究性症状治疗，包括认知障碍和精神病，这些症状可能会给LBD患者及其护理人员带来巨大负担。最近的发现：我们回顾了11种前瞻性疾病改良疗法（DMT），包括4种具有2期数据的疗法（奈夫拉马匹莫、尼洛替尼、博苏替尼和E2027）；四个有症状人群的数据有限，包括1期、开放标签、登记或队列数据（伏达替尼、氨溴索、克伦特罗和特拉唑嗪）；三个是健康人群中的1期数据（Anle138b、fosgonimeton和CT1812）。我们还评估了四种治疗认知障碍的症状疗法，但出于安全性和疗效考虑，只有NYX-458仍在积极研究中。在最近研究的精神病症状疗法中，匹马凡色林在LBD中显示出前景，但对内洛他林的研究已暂停。尽管发现新的症状和疾病改善疗法仍然是一个重大挑战，但最近发表和即将进行的试验表明，朝着这一目标迈出了有希望的步伐。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Neurology and Neuroscience Reports 医学-临床神经学

CiteScore

9.20

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Current Neurology and Neuroscience Reports provides in-depth review articles contributed by international experts on the most significant developments in the field. By presenting clear, insightful, balanced reviews that emphasize recently published papers of major importance, the journal elucidates current and emerging approaches to the diagnosis, treatment, management, and prevention of neurological disease and disorders. Presents the views of experts on current advances in neurology and neuroscience Gathers and synthesizes important recent papers on the topic Includes reviews of recently published clinical trials, valuable web sites, and commentaries from well-known figures in the field.